K. G. Jebsen Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.
Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway.
J Thromb Haemost. 2017 Feb;15(2):295-303. doi: 10.1111/jth.13587. Epub 2017 Feb 6.
Essentials Reports on recurrence and mortality after a first venous thromboembolism (VTE) vary considerably. We describe rates of recurrence and mortality in patients with a first VTE from the Tromsø study. The overall recurrence rate was 3.9 per 100 person-years, but this varied widely with time. Despite advances in VTE management, the rates of adverse events are still fairly high.
Background Previous reports on recurrence and mortality rates after a first episode of venous thromboembolism (VTE) vary considerably. Advances in the management and treatment of VTE during the last 15 years may have influenced the rates of clinical outcomes. Aim To estimate the rates of recurrence and mortality after a first VTE in patients recruited from a large population-based cohort. Method From the Tromsø study, patients (n = 710) with a first, symptomatic, objectively confirmed VTE were included and followed in the period 1994-2012. Recurrent episodes of VTE were identified from multiple sources and carefully validated by review of medical records. Incidence rates and cumulative incidence rates with 95% confidence intervals (CIs) of VTE recurrence and mortality were calculated. Results The mean age of the patients was 68 years (range 28-102 years), and 166 (23.4%) had cancer at the time of first VTE. There were 114 VTE recurrences and 333 deaths during a median study period of 7.7 years (range 0.04-18.2 years). The risk of recurrence was highest during the first year. The overall 1-year recurrence rate was 7.8 (95% CI 5.8-10.6) per 100 person-years (PY), whereas the recurrence rate in the remaining follow-up period (1-18 years) was 3.0 (95% CI 2.4-3.8) per 100 PY. The overall 1-year all-cause mortality rate was 29.9 (95% CI 25.7-34.8) per 100 PY, and in those without cancer the corresponding rate was 23.6 (95% CI 17.8-31.3) per 100 PY. Conclusion Despite advances in VTE management, the rates of adverse events remained fairly high, particularly in the first year following a first VTE.
先前关于首次静脉血栓栓塞症(VTE)后复发和死亡率的报告差异很大。在过去的 15 年中,VTE 的管理和治疗进展可能影响了临床结果的发生率。目的:估计首次 VTE 后患者的复发和死亡率,这些患者来自大型基于人群的队列。方法:从特罗姆瑟研究中,纳入了 710 例首次出现有症状、客观证实的 VTE 的患者,并在 1994 年至 2012 年期间进行随访。通过多种来源识别复发性 VTE,并通过病历审查仔细验证。计算 VTE 复发和死亡率的发生率和累积发生率,置信区间(CI)为 95%。结果:患者的平均年龄为 68 岁(范围 28-102 岁),166 例(23.4%)在首次 VTE 时患有癌症。在中位研究期间(0.04-18.2 年),发生了 114 例 VTE 复发和 333 例死亡。复发风险在第一年最高。总体 1 年复发率为 7.8(95%CI 5.8-10.6)/100 人年(PY),而在剩余随访期间(1-18 年)的复发率为 3.0(95%CI 2.4-3.8)/100 PY。总体 1 年全因死亡率为 29.9(95%CI 25.7-34.8)/100 PY,无癌症患者的相应死亡率为 23.6(95%CI 17.8-31.3)/100 PY。结论:尽管 VTE 管理有所进步,但不良事件的发生率仍然相当高,尤其是在首次 VTE 后第一年。